Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Sep 17;8(9):e61361.
doi: 10.1371/journal.pone.0061361. eCollection 2013.

Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis

Liping Zhuang et al. PLoS One. .

Abstract

Background: The effect of interferon(IFN) in the management of hepatocellular carcinoma (HCC) remains controversial, and no clear recommendations have been proposed.

Objectives: To evaluate the effect and safety of IFN for HCC.

Methods: PubMed, OvidSP, and Cochrane Library were searched from their establishment date until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated and then subjected to meta-analysis.

Results: Thirteen randomized control trials (RCTs) involving 1344 patients were eligible for this study. When IFN was used as an adjuvant therapy for HCC patients after curative therapy, the meta-analysis showed that IFN reduced the 1-, 2-, 3-, 4-, and 5-year recurrence rates. Subgroup analysis showed that IFN reduced the 2-, 3-, 4-, and 5-year recurrence rates of hepatitis C viral (HCV)-related HCC. The effect of IFN for on hepatitis B virus(HBV)-related HCC patients could not be determined because of isufficient data. After surgical resection, adjuvant IFN therapy reduced the 4- and 5- recurrence rates. All studies reported that IFN could not improve the overall survival of HCV-realated HCC patients after curative therapies. Only one study showed that IFN was associated with better overall survival in HCC patients after curative therapy and subgroup of HCC patients after surgical resection. Thus, meta-analysis was not performed. Different treatment options were used as control to study the effect of IFN for intermediate and advanced HCC patients, thus meta-analysis was not appropriate. All included studies, except for one, reported that IFN treatment was well tolerated.

Conclusions: After curative therapies, adjuvant IFN reduced the recurrence of HCC. IFN did not improve the survival of HCV-related HCC patients after curative therapy. Whether IFN is effective for intermediate and advanced HCC patients could not be determined because of insufficient data. The toxicity of IFN was acceptable.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

Cited by

References

    1. Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global Cancer Statistics. CA CANCER J CLIN 61: 69–90. - PubMed
    1. El-Serag HB (2002) Hepatocellular carcinoma: An epidemiologic view. J Clin Gastrogenterol 35: S72–78. - PubMed
    1. Altekruse SF, Mcglynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485–1491. - PMC - PubMed
    1. Bruix J, Sherman M (2010) Management of hepatocellular carcinoma: An update. AASLD Practice Guidelines; Available: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%.... Accessed 2013 March 26.
    1. Nathan H, Schulick RD, Choti MA, Pawlik TM (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249: 799–805. - PubMed

Publication types